Clinical Trial Update: Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating obinutuzumab with GDP chemotherapy in relapsed or refractory non-Hodgkin lymphoma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Decadron (Dexamethasone)
• Gazyva (Obinutuzumab)
• Gemzar (gemcitabine)
• Platinol (cisplatin)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Lymphoma, Non-Hodgkin's | Phase 2 | Status: COMPLETED